Cell therapy is a sub-type of Regenerative Medicine that treats a disease via introducing new cells into a tissue. Together with pharma, biological and medical devices, cell therapy today has become the fourth and most recent therapeutic pillar of global healthcare. Cell therapy has many potential forms, including Cell Replacement Therapy, Cell-based Gene Therapy, and the transplantation of stem cells or progenitor cells (autologous or allogeneic). Here at ReLife, we apply adipose-derived stem cells to treat many complicated conditions. Adipose tissue is full of adipose stem cells, which have the ability to be easily cultivated in vitro and in a multiple differentiation capacity. It can effectively participate in the regenerative and repair procedures of both tissue and organs. Adipose stem cells are easy to be collected and cultivated into multiple stem cells with only a little adipose tissue, which can effectively reduce the injury to the patient. Due to its stable proliferation, low decay rate, abundant storage ability in the body, as well as it’s suitability for autologous transplantation, adipose stem cell therapy has been a hot research focus in stem cell area recently. There are two significant advantages of adipose stem cells:
- No rejection: the adipose stem cells applied from transplantation are derived from patient’s own adipose tissue via liposuction, which can avoid allorecognition so as to avoid infection, rejection, etc.
- Safe procedure: multiple stem cells will be cultivated with only a little adipose tissue, which can reduce the injury to the patient with only a minor wound.
Adipose tissue is an active endocrine and paracrine organ, which secretes various cytokines and biological factors. The regular secretion of adipose tissue regulates and controls the balance of energy in the body, and also plays a role in the inflammation procedure. Adipose is full of adipose stem cells as well as adipose tissue. Adipose stem cells have the ability to be easily cultivated in vitro and multiple differentiation capacity. With transplantation of both adipose tissue and adipose stem cells, the paracrine function of adipose tissue enables the adipose stem cells to function better. ReLife is dedicated to providing every patient the most effective and safe treatment approach. Here we apply adipose stem cell as the HGF carrier in our gene therapy, which combines stem cell therapy with gene therapy in order to attain best treatment results. By taking advantage of adipose stem cell tropism, HGF will be carried to the lesion region by adipose stem cells, enabling HGF to continuously and stably effect and improve the blood circulation, as well as improving the survival rate and efficiency of adipose stem cells, which makes the treatment effect much better than single application of stem cell therapy or gene therapy. It plays a key role in treating many complicated disorders that cannot be treated well with conventional methods, repairing the function of disease or dysfunctional tissue and organs, and improving the general condition of the patient. For more information about the treatment procedure and other detailed information, please refer to “Gene Therapy“.
With decades of devotion to the internal medicine field at a state-established hospital, Dr. Zhang specializes in clinical research of Infertility, Alzheimer’s Disease, Diabetes Mellitus, breast disease, hepatic disorders in the late stage, malignant tumors etc. With integration of the latest international treatment techniques and Traditional Chinese Medicine, Dr.Zhang has successfully treated many rare disorders. Dr.Zhang has participated in many important medical academic forums and received two awards for her excellent work, including one second-honor award and one third-honor award. Besides medical science recognition, her academic achievements also include her many published medical dissertations. Currently, Dr. Zhang is also a Guest Lecturer of “National Public Nutritionists Training” program as invited by Peking University.
Dr. Wu has focused on stem cell research, immunological cell research as well as clinical research for decades. He developed cell culture kits for cytokine-induced killer (CIK) cells, dendritic cells (DCs) and natural killer (NK) cells. He took charge of the Chinese national support 863 projects “Pre-clinical Study on Bio-therapy of Malignant Tumor with Human Wild-Type p-53, GM-CSF and B7-1 Genes Mediated by Recombinant Adenovirus Vector” (2001AA217041) and “Gene Therapy with Human Hepatocyte Growth Factor for Treating Ischemic Vascular Disease and Pathological Scar (2001AA217061, 2003AA216081). The “Recombinant Adenovirus – Hepatocyte Growth Factor Injectors” and “Recombinant Plasmid – Hepatocyte Growth Factor Injectors” he developed were respectively approved by China Food and Drug Administration with Type I new drug clinical approval of biological product in 2005 and 2007 (Approval No. 2005L01181, 2007L01482). The “Recombinant Adenovirus – Hepatocyte Growth Factor Injectors” received stage II drug clinical trial approval (Approval No. 2009L01499).